Issues related to tobacco industry and tobacco products, including FDA's pending flavored cigar product standard; PMTA process; and need for reform to Center for Tobacco Products.
Duration: February 7, 2019
to
present
General Issues: Tobacco , Health Issues , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Budget/Appropriations
Spending: about $8,305,725 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate, Office of Management & Budget (OMB), Executive Office of the President (EOP), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Vice President of the U.S.
Affiliated organizations: Swisher International Inc.; E-Alternative Solutions; Hay Island Holding Company
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Swisher International, Inc., f/k/a SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 19.
Original Filing: 301567235.xml
Lobbying Issues
Issues related to tobacco industry and tobacco products, including FDA's pending flavored cigar product standard; PMTA process; and need for reform to Center for Tobacco Products.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301530042.xml
Lobbying Issues
Issues related to tobacco industry and tobacco products; FDA's pending flavored cigar product standard.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to tobacco industry and tobacco products, including FDA's pending flavored cigar product standard
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301514054.xml
Lobbying Issues
Issues related to tobacco industry and tobacco products including premium cigar issues; FDA's pending flavored cigar product standard.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to tobacco industry and tobacco products including FDA and CTP processes; FDA's pending flavored cigar product standard.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301482245.xml
Lobbying Issues
Issues related to tobacco industry and tobacco products; FDA's pending flavored cigar product standard.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301456729.xml
Lobbying Issues
Issues related to tobacco industry and tobacco products.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301434896.xml
Lobbying Issues
Issue related to tobacco industry and tobacco products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Oct. 18, 2022.
Original Filing: 301407549.xml
Lobbying Issues
Issue related to tobacco industry and tobacco products, including the FDA rule on flavored cigars.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301394233.xml
Lobbying Issues
Issue related to tobacco industry and tobacco products, including the FDA rule on flavored cigars.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301365304.xml
Lobbying Issues
Issue related to tobacco industry and tobacco products, including the pending FDA rule on flavored cigars. Issues related to the regulation of synthetic nicotine, including H.R. 2471, the Consolidated Appropriations Act of 2022.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301332858.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Congressional outreach and monitoring related to federal excise taxes, including:
-H.R. 2786 / S. 1314, Tobacco Tax Equity Act.
-H.R. 5376, Build Back Better Act.
Congressional outreach and monitoring related to Congressional priorities on tobacco products and flavorings.
Monitoring related to H.R. 4356 / S. 2599, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2022.
Monitored the following:
-FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28)
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301314231.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Congressional outreach and monitoring related to federal excise taxes, including:
-H.R. 3407 / S. 411, MOMMA's Act.
-H.R. 2786 / S. 1314, Tobacco Tax Equity Act.
-H.R. 5376, Build Back Better Act.
Congressional outreach and monitoring related to Congressional priorities on tobacco products and flavorings.
Congressional outreach and monitoring related to H.R. 4356 / S. 2599, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2022.
Monitored the following:
-FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28)
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored the Build Back Better Act (H.R. 5376) for implications on international trade and supply chain issues.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301288297.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Congressional outreach and monitoring related to federal excise taxes, including:
-H.R. 3407 / S. 411, MOMMA's Act.
-H.R. 2786 / S. 1314, Tobacco Tax Equity Act.
Congressional outreach and monitoring related to Congressional priorities on tobacco products and flavorings.
Congressional outreach and monitoring related to H.R. 4356 /Senate draft, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2022.
Outreach and monitoring related to federal COVID-19 relief and stimulus legislation including:
-H.R. 1319, American Rescue Plan Act of 2021.
Monitored the following:
-FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28)
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301263152.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Outreach and monitoring related to federal COVID-19 relief and stimulus legislation.
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.
Monitored the following:
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28)
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Outreach and monitoring related to federal COVID-19 relief and stimulus legislation.
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees.
Monitored the following:
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28)
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301242778.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Outreach and monitoring related to federal COVID-19 relief and stimulus legislation.
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, and tobacco product user fees.
Monitored the following:
H.R. 133, FY 2021 Omnibus and COVID Relief and Response Act.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
S. 1253 / H.R. 3942, Preventing Online Sales of E-Cigarettes to Children Act.
Monitored the following:
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301219443.xml
Lobbying Issues
Outreach and monitoring related to the tobacco industry.
Outreach and monitoring related to federal COVID-19 relief and stimulus legislation.
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, and tobacco product user fees.
Monitored the following:
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
S. 1253 / H.R. 3942, Preventing Online Sales of E-Cigarettes to Children Act.
Monitored the following:
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301199947.xml
Lobbying Issues
Congressional outreach and monitoring related to the tobacco industry.
Monitored the following:
-Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
-Federal and legislative action related to the marketing and advertising of tobacco products.
-FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
-FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
-FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
-FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661)
-FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
Outreach and monitoring regarding:
-Coronavirus and related economic impacts;
-Stimulus provisions in relief bills, such as P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and H.R. 6800, The Heroes Act.
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, and tobacco product user fees.
Monitored the following:
S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
S. 655 / H.R. 1498, SAFE Kids Act.
S. 1541, Tobacco-Free Youth Act.
S. 2463, E-Cigarette Tax Parity Act.
S. 2517, Tobacco Tax Equity Act of 2019.
S. 3174, Reversing the Youth Tobacco Epidemic Act of 2020.
H.R. 293, Youth Vaping Prevention Act of 2019.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019.
H.R. 4742, Protecting American Lungs Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301176607.xml
Lobbying Issues
Congressional outreach and monitoring related to the tobacco industry.
Monitor the implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
Monitor federal and legislative action related to the marketing and advertising of tobacco products.
Outreach and monitoring related to FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, tobacco 21, online sales bans, and tobacco product user fees.
Outreach and monitoring regarding the following:
S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
S. 655 / H.R. 1498, SAFE Kids Act.
S. 1258 / H.R. 2411, Tobacco to 21 Act.
S. 1541, Tobacco-Free Youth Act.
S. 2463, E-Cigarette Tax Parity Act.
S. 2517, Tobacco Tax Equity Act of 2019.
S. 3174, Reversing the Youth Tobacco Epidemic Act of 2020.
H.R. 293, Youth Vaping Prevention Act of 2019.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019.
H.R. 4742, Protecting American Lungs Act of 2019.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301128536.xml
Lobbying Issues
Congressional outreach and monitoring related to the tobacco industry.
Monitor the implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
Monitor federal and legislative action related to the marketing and advertising of tobacco products.
Outreach and monitoring related to FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
Outreach and monitoring related to FDA operations and tobacco policy on the following issues: proposed flavor restrictions, tobacco 21, online sales bans, and tobacco product user fees.
Outreach and monitoring regarding the following:
S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
S. 655 / H.R. 1498, SAFE Kids Act.
S. 1048 / H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction.
S. 1253 / HR 3942, Preventing Online Sales of E-Cigarettes to Children Act.
S. 1258 / H.R. 2411, Tobacco to 21 Act.
S. 1541, Tobacco-Free Youth Act.
S. 1895, Lower Health Care Costs Act, provisions related to tobacco control.
S.2463, E-Cigarette Tax Parity Act.
H.R. 293, Youth Vaping Prevention Act of 2019.
H.R. 2084, SCOTT Act of 2019.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019.
H.R. 1865, FY 2020 Consolidated Appropriations Act; Agriculture and Health and Human Services Titles.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301075701.xml
Lobbying Issues
Congressional outreach and monitoring related to the tobacco industry.
Monitor the implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
Monitor federal and legislative action related to the marketing and advertising of tobacco products.
Outreach and monitoring related to FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
Outreach and monitoring related to the following:
S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
S. 655 / H.R. 1498, SAFE Kids Act.
S. 1048 / H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction.
S. 1253 / HR 3942, Preventing Online Sales of E-Cigarettes to Children Act.
S. 1258 / H.R. 2411, Tobacco to 21 Act.
S. 1541, Tobacco-Free Youth Act.
S. 1895, Lower Health Care Costs Act, provisions related to tobacco control.
S.2463, E-Cigarette Tax Parity Act.
H.R. 293, Youth Vaping Prevention Act of 2019.
H.R. 2084, SCOTT Act of 2019.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
H.R. 4425, Quell Underage Inhaling of Toxic Substances Act of 2019.
S. 2522 / H.R. 3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020.
H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020.
Senate Draft Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301056854.xml
Lobbying Issues
Congressional outreach and monitoring related to the tobacco industry.
Monitor the implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
Monitor federal and legislative action related to the marketing and advertising of tobacco products.
Outreach and monitoring related to FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
Outreach and monitoring related to the following:
S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
S. 655 / H.R. 1498, SAFE Kids Act.
S. 1258 / H.R. 2411, Tobacco to 21 Act.
S. 1541,Tobacco-Free Youth Act.
H.R. 293, Youth Vaping Prevention Act of 2019.
H.R. 2084, SCOTT Act of 2019.
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019.
H.R. 3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020.
Senate Draft Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020.
H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020.
Senate Draft Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, SI GROUP CLIENT SERVICES had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301038037.xml
Lobbying Issues
Congressional and Administrative outreach and monitoring related to the tobacco industry.
Monitor the implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3).
Monitor federal and legislative action related to the marketing and advertising of tobacco products.
Outreach and monitoring related to FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565)
Outreach and monitoring related to FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107)
Outreach and monitoring related to S. 9 / H.R. 1854, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
SI GROUP CLIENT SERVICES filed a lobbying registration on Feb. 28, 2019 for in-house lobbying efforts, effective Feb. 7, 2019.
Original Filing: 301020820.xml
Issue(s) they said they’d lobby about: Administrative and legislative outreach and monitoring on issues related to the tobacco and vaping industries. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...